All conditions

Cervical Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

180
Trials on record
29
Recruiting now
0
Australian sites
3
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Cervical Cancer →

Get alerts when Cervical Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Cervical Cancer

Cervical cancer is a type of cancer that starts in the cells of the cervix, which is the lower part of the uterus (womb) that connects to the vagina. Most cases are caused by certain strains of the human papillomavirus, or HPV, a very common virus that many people carry at some point in their lives without knowing it. When some HPV infections do not clear on their own, they can over many years cause normal cervical cells to change and eventually become cancerous. Cervical cancer is generally grouped by how far it has spread, which doctors call the "stage," and this plays a big role in how it is managed.

In Australia, cervical cancer affects around 900 women each year, making it one of the less common cancers compared to some others, partly because of the success of the national HPV vaccination program and the cervical screening program. It most commonly affects women between the ages of 25 and 45, though it can occur at other ages too. Aboriginal and Torres Strait Islander women are diagnosed at higher rates and at later stages, which health services are actively working to address.

Treatment for cervical cancer in Australia is coordinated through specialist medical teams and will depend on factors such as the stage of the cancer, the person's age, and overall health. Options that doctors commonly discuss include surgery to remove the affected tissue or uterus, radiation therapy, chemotherapy, or a combination of these approaches. For cancers caught at an early stage, outcomes are generally very positive. A team of different specialists, including gynaecological oncologists, radiation oncologists, and nurses, typically work together to plan care. It is completely reasonable to ask your medical team as many questions as you need, and to bring a support person with you to appointments.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Cervical Cancer in Australia right now? Here's what's publicly known.

  • No PBS-subsidised medicines are currently mapped for Cervical Cancer on Voxsanity. Your doctor or pharmacist can advise on what may be available.
  • No trials currently recruiting at Australian sites right now. Worldwide trials may still be an option. See the trial list below.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Cervical Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Cervical Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Cervical Cancer by country. Australia is highlighted.

Showing the top 10 of 29 countries with trial sites.

Clinical trials for Cervical Cancer

Showing 29 of 29 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

NCT05046080 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of cervical cancer called clear cell carcinoma, and who received that diagnosis at MD Anderson Cancer Center (MDACC) Who may not be able to join: - No specific exclusion criteria were listed in the official trial information (c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05197881 · Varian, a Siemens Healthineers Company Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced cervical cancer (specific types: squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma) that has been confirmed by tissue testing, is newly diagnosed, and falls within certain stages of spread — but has not reac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05378087 · Chongqing University Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study. - Your cervical cancer has been confirmed by a tissue sample (biopsy) as one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma. - Your cancer is at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05390567 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 25 to 65, based on American Cancer Society screening recommendations - People who were assigned female sex at birth - People who have not previously had cervical cancer - People who have not previously had a hysterectomy (surgical removal of the uterus) - People who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05829629 · BlueSky Immunotherapies GmbH Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2025
🇸🇰 SK

**Who might be able to join this trial:** - Women aged 18 to 49 who have been infected with a specific strain of HPV called HPV16, and whose cervical cell test results show either normal cells or only mild/low-grade changes - People whose HPV16 infection has been confirmed by two separate validated tests, taken at lea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05950087 · Guizhou Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old. - People who have had cervical cancer confirmed through a tissue sample (biopsy or pathology test). - People who are able to have imaging scans such as PET/CT, and who are able to attend all required follow-up appointments. - People who have a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06079671 · AstraZeneca Phase 3 · 19 countries Recruiting
Recruiting Phase 3 Est. completion 26 November 2027
🇧🇷 BR🇨🇦 CA🇨🇳 CN🇩🇰 DK🇩🇪 DE🇮🇳 IN🇮🇹 IT🇯🇵 JP +11 more

**Who might be able to join this trial:** - The participant must be female. - The participant must be at least 15 years old at the time of screening (for those under 18, physical development must be at a certain stage of puberty, known as Tanner Stage III — confirm with trial site). - The participant must weigh more t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06109870 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

Who might be able to join this trial: - People who are willing to sign and date a consent form agreeing to take part - People who currently live in the Rio Grande Valley or another low-resource community in Texas - People who are willing to follow all of the study's procedures - People who are female and aged 25 years...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06391190 · RenJi Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with locally advanced cervical cancer that has not yet been treated, confirmed by a laboratory tissue test - People who are generally active and able to carry out daily activities with little or no limi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06403618 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 June 2025
🇮🇹 IT

Who might be able to join this trial: - People who were 18 years of age or older when they were diagnosed - People who have had a tissue sample (biopsy) or a small surgical procedure confirm a cervical cell change called CIN2 - People who have a known HPV (Human Papillomavirus) test result from the time of their diagno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06455605 · Darell Bigner Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of joining the study. - People who have been diagnosed with a specific type of aggressive brain tumour called Grade 4 IDH-wildtype Glioblastoma (or a high-grade brain tumour with similar molecular features), confirmed by laboratory testing...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06500767 · University of Turin, Italy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇮🇹 IT

Who might be able to join this trial: - People attending a Colposcopy service through the Prevenzione Serena screening program, referred because of an abnormal Pap smear result or two consecutive positive HPV test results - People whose biopsy result showed a high-grade abnormality (HSIL) in cervical cells - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06515301 · Addis Ababa University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2025
Ethiopia

Who might be able to join this trial: - Women between the ages of 30 and 49 who do not have HIV - Women aged 26 or older who are living with HIV - Women who have already received treatment for a suspicious cervical lesion that was found through a VIA screening (a type of visual cervical check using a vinegar solution)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06618703 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2030
🇫🇷 FR

**Who might be able to join this trial:** - Children and young people aged 4 years old or older, but younger than 18 years old, at the time of joining the trial - People who received radiation therapy to part or all of the brain for cancer or a blood cancer before the age of 16 - People for whom the radiation therapy f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06650956 · Health Poverty Action Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
Laos

Who might be able to join this trial: - Girls aged 10 to 13 years old, who would receive HPV vaccination and sexual and reproductive health (SRH) education - Boys aged 10 to 13 years old, who would receive sexual and reproductive health (SRH) education - Boys and girls aged 10 to 13 years old who attend one of the rand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06658405 · Centre Oscar Lambret Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇫🇷 FR

**Who might be able to join this trial:** **Criteria that apply to both groups:** - People who are female and over 45 years old - People who have been treated with a cone biopsy (a surgical procedure to remove abnormal tissue from the cervix) for a high-grade abnormal cervical lesion - People whose HPV test came back...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06670911 · Instituto Nacional de Cancer, Brazil Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇧🇷 BR

**Who might be able to join this trial:** - Women aged 18 years or older - People diagnosed with cervical cancer (squamous cell, adenocarcinoma, or adenosquamous type) that has come back, persisted, or spread to other parts of the body, and whose cancer tests positive for a protein called PD-L1 (with a score of 1 or h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06843720 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2029
🇺🇸 US

**Who might be able to join this trial:** This trial involves several different groups of people. Depending on which group applies, the criteria are: **Patients eligible for cervical cancer screening:** - People who currently live in the state of Texas - People who receive care at a clinic that is partnering with thi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06850974 · Stony Brook University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
Mozambique

Who might be able to join this trial: - Women aged 18 or older who are attending Hospital Central de Maputo and need to end a pregnancy for a legally accepted reason, at 16 to 21 weeks of pregnancy - People who speak Portuguese Who may not be able to join: - People under the age of 18 - People who are currently in pri...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06982976 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with high-grade precancerous cell changes in the cervix or vagina (called HSIL, CIN2, CIN3, VaIN2, or VaIN3), confirmed by a specialist examination (colposcopy) and tissue sample (biopsy), or who have lower-grade changes (CIN1 or VaIN1) that hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07009327 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with CIN3 (a high-grade abnormality of the cervix) who are being considered for photodynamic therapy (a light-based treatment) - People with a type 1 or type 2 transformation zone (a specific area of the cervix), where a colposcopy examination (a close-up exa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07061977 · National Cancer Institute (NCI) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with cervical cancer that has been confirmed by a tissue test (pathology), specifically one of these types: squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma - People whose cervical cancer is locally advanced, meani...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07168200 · Shanghai Shengdi Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and able to sign a consent form agreeing to join the study. - You are able to provide a tissue sample from a primary or secondary (spread) cancer. - You have at least one tumor that can be measured on a scan. - Your doctor expects you to live for...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07169734 · Alentis Therapeutics AG Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 5 April 2029
🇫🇷 FR Hong Kong🇮🇹 IT🇳🇱 NL🇸🇬 SG🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed through lab testing (tissue/cell samples) to have one of these cancers that has spread: colorectal cancer, bile duct cancer (intrahepatic cholangiocarcinoma), squamous non-small cell lung cancer, bladder/urinary tract cancer (urothelial carcinoma), or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07171658 · Jessica Di Vincenzo Sormani Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇭 CH

Who might be able to join this trial: - Women who have received a Breast Cancer Screening invitation letter in one of five Swiss regions: Geneva, Bern (French-speaking area), Jura, Neuchâtel, or Vaud - Women aged between 50 and 74 years old - Women who have not had a cervical cancer screening test in the past three yea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07196033 · Tata Memorial Hospital Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 15 March 2028
🇮🇳 IN🇯🇵 JP🇹🇭 TH

Who might be able to join this trial: - People who have been diagnosed with cervical cancer at a specific stage (FIGO 2018 stage IB to IVA), where the cancer is one of three particular types: squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. - People whose treatment plan includes a combination of che...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07286253 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2027
🇨🇳 CN

Who might be able to join this trial: - People who have given written agreement to take part, or whose immediate family member has done so on their behalf if they are unable to. - Women aged 18 to 70 years old at the time of signing the consent form. - People with a laboratory-confirmed diagnosis of cervical cancer tha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07338487 · Second Xiangya Hospital of Central South University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part in the study. - You are 18 years old or older when you join the trial. - You are able to carry out basic daily activities, with any limitations ranging from fully active to capable of self-care but unable to work (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07550010 · University Hospital, Geneva Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 September 2026
Cameroon

Who might be able to join this trial: - Women who are HIV-negative and between 30 and 49 years old, or women who are HIV-positive and between 25 and 49 years old - People who are able to understand what the study involves and are willing to take part by signing a consent form Who may not be able to join: - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Cervical Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Australian Cervical Cancer Foundation (ACCF) is the national body for cervical cancer support and awareness.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.